|
(Health-NewsWire.Net, September 26, 2019 ) Market Overview:
The Companion Diagnostics Market was valued at USD xx million in 2019. The research at DMI yielded diverse opinions about the market with the global Companion Diagnostics market forecast valuation pegged at USD xx million by 2026.
The research also revealed that the global Companion Diagnostics Market size is expected to grow at a CAGR of xx% during the forecast period (2019-2026).
Market Dynamics:
The market is driven by several factors such as increased incidences of cancer, growing need for targeted therapies and favorable regulatory laws. The high cost of the drug development and lack of skilled professionals are the restraining factors that can affect the further growth of the market.
Market Segmentation:
The Companion Diagnostics market is segmented by Technology into Polymerase Chain Reaction, Next-Generation Sequencing, In-situ Hybridization, Immunohistochemistry, and Others.
The polymerase chain reaction (PCR) segment accounted for the largest chunk of global companion diagnostics market share in 2016 due to the ease of use as it does not require too many samples for biomarker identification. The next-generation sequencing (NGS) segment is projected to grow during the forecast period.
Based on Indications, the market is segmented into Oncology (Colorectal Cancer, Leukemia, Breast Cancer, Lung Cancer, Others), Neurology, and Others.
The oncology segment occupies the largest part of the global companion diagnostics market share and is also the fastest growing segment due to increasing cases of cancer cases globally and rising number of clinical trials targeting cancer biomarkers for lung, breast, and prostate cancers.
Based on End User, the market is segmented into Pharmaceutical and Biopharmaceutical Companies, Research Laboratories, and Others. In 2016, the pharmaceutical and biopharmaceutical companies segment was the largest in terms of global companion devices market share and is estimated to grow during the forecast period due to increasing use of companion diagnostic kits among pharmaceutical and biopharmaceutical companies.
Geographical Analysis:
By Geography, the market is segmented into, North America, Europe, South America, Asia Pacific, The Middle East and Africa
Competitive Analysis:
The major companies in the Companion Diagnostics market includes F. Hoffmann-La Roche AG, Agilent Technologies Inc., Qiagen N.V., Thermo Fisher Scientific Inc., Abbott Laboratories, Inc., Biomérieux SA, Danaher Corporation, Illumina Inc., Myriad Genetics Inc., Arup Laboratories Inc., Sysmex Corporation, Hologic Inc., Novartis AG, Almac Group, and Abnova Corporation.
View full report: https://www.datamintelligence.com/research-report/companion-diagnostics-market
Download free sample: https://www.datamintelligence.com/download-sample/companion-diagnostics-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
